Fortress Biotech, Inc. (FBIOP) Stock Price & Analysis
Fortress Biotech, Inc. (FBIOP) — MoonshotScore 37/100 (Weak band), calculated Nov 18, 2026. Price $13.95 (+1.64%), as of the Nov 18, 2026 trading session; market cap $56.5M.
Educational signal · not a buy or sell recommendation · How to read this
Fortress Biotech, Inc. · FBIOP
Fortress Biotech, Inc. is a biopharmaceutical company focused on developing and commercializing pharmaceutical and biotechnology products, including dermatology treatments and oncology therapies. The company operates through a network of subsidiary companies and collaboration arrangements to advance its pipeline.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Fortress Biotech (FBIOP)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and durable growth, at a cheap price. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Elite; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Rising.
- Altman Z -2.31 · Piotroski F 6
- ROE 102.5% · ROA -8.1% · current ratio 2.93
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 35 | Weak | |
| 38 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 37 | Weak | |
| 37 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $13.95 | |
| Change on the day | +1.64% | |
| 52-week range | $6.50 – $21.43 | |
| Market capitalisation | $56.5M | |
| Price / earnings (trailing) | 0.62 | |
| Shares traded on the day | 10.6K |
Price & events
Other perspectives
Council score for Fortress Biotech (FBIOP): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Simons-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Fortress Biotech (FBIOP), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Fortress Biotech, Inc. (FBIOP) is the company analyzed here. It employs 78 people and is led by Lindsay A. Rosenwald. The market values it at $56.5M.
What are the financial strengths and risks for Fortress Biotech (FBIOP)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z -2.31 · Piotroski F 6. Trailing ratios: ROE 102.5% · ROA -8.1% · current ratio 2.93.
How does Fortress Biotech compare with its peers?
Short answer
Fortress Biotech's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.02 Nov 18, 2026 | $255M | 90 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.96 Nov 18, 2026 | $186M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $3.29 Nov 18, 2026 | $505M | 60 5-pillar Nov 18, 2026 | |
| $6.89 Nov 18, 2026 | $550M | 60 5-pillar Nov 18, 2026 | |
| $1.10 Nov 18, 2026 | $90.6M | 53 5-pillar Nov 18, 2026 | |
| Fortress Biotech (FBIOP) — this page | $13.95 | $56.5M | 37 |
| $4.76 Nov 18, 2026 | $39.8M | 34 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 2
- Identified insiders
- 1
- Purchases
- 0
- Sales
- 0
- Other transactions
- 2
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held FBIOP in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported FBIOP in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Fortress Biotech (FBIOP)?
Common Questions About FBIOP
These answers are editorial: 1 of these 9 answers is drawn from the FBIOP research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for FBIOP?
FBIOP carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is FBIOP a good stock to buy?
Stock Expert AI does not rate FBIOP buy, sell or hold. Fortress Biotech, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the FBIOP stock price today?
The last price recorded for Fortress Biotech, Inc. (FBIOP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for FBIOP?
The main risks for Fortress Biotech, Inc. include clinical trial failures, regulatory setbacks, and market competition. The company's success depends on the successful development and commercialization of its product candidates, which are subject to regulatory approval. Investors should carefully consider these risks before investing in FBIOP.
What are the key factors to evaluate for FBIOP?
Fortress Biotech, Inc. (FBIOP) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does FBIOP data refresh on this page?
FBIOP's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven FBIOP's recent stock price performance?
Fortress Biotech, Inc. (FBIOP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline of product candidates. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FBIOP overvalued or undervalued right now?
The trailing P/E of Fortress Biotech, Inc. (FBIOP) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research FBIOP before investing?
Before investing in Fortress Biotech, Inc. (FBIOP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com